Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy
Plasma lipid and lipoprotein levels were measured at baseline and after 8 weeks of highly active antiretroviral therapy among patients receiving delavirdine with or without a protease inhibitor (PI). In patients receiving nucleoside reverse transcriptase inhibitors (NRTI) plus delavirdine, there was a statistically significant increase in cholesterol and HDL levels, whereas those receiving NRTI plus a PI had no significant change in their HDL levels. When delavirdine was combined with a PI, there was a more dramatic increase in both cholesterol and HDL concentrations.
Roberts, A., Liappis, A., Chinn, C., Parenti, D., Muesing, R., Schuck, S., Hsia, J., & Simon, G. (2002). Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. AIDS, 16 (13). http://dx.doi.org/10.1097/00002030-200209060-00018